CXCL12 and myelodysplastic syndrome: To assess the clinical relevance, we determined the SDF-1 levels in bone marrow plasma from a small cohort of MDS patients with SF3B1 mutation before and after receiving luspatercept [10] and detected a tendency for increased levels of SDF-1 post treatment that was most notable in the clinical responders.